Actualizing the Untapped Potential of the Innate Immune System

Affimed’s approach to advancing immuno-oncology

read more

Events

30Sep

NK2019

September 30 - October 3, 2019 (Luxembourg)

more events

Our Mission

We are a team of innate immunity experts unrelenting in our efforts to change the meaning of cancer

With our differentiated approach to arming the body’s innate immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.

read more

Affimed (NASDAQ: AFMD) pioneers immune cell engagement, employing its insights and scientific expertise to harness the body’s innate immune systems in the fight against cancer and other life-threatening diseases. Our proprietary ROCK® (Redirected Optimized Cell Killing) platform allows for the modular design of tetravalent bi- and multi-specific antibodies, including first-in-class innate and adaptive cell engager products.

read less

Our Approach

Redirecting innate cells to recognize and kill tumor cells

We are actualizing the next advancement in immuno-oncology (I-O) through our proprietary ROCK® platform, which stands for Redirected Optimized Cell Killing. Our new approach to build ROCK® based innate cell engagers aims to treat a broad range of hematologic and solid tumors by countering tumor immune evasion through activating a patient’s own innate immune system.

read more about our approach

Our Pipeline

Targeting hematological and solid tumors with differentiated and versatile innate cell engagers

Our ROCK® platform-designed tetravalent bispecific innate cell engagers are being studied in a number of clinical and preclinical programs. These innate cell engagers are the first to demonstrate a favorable safety profile and promising signs of therapeutic efficacy.

learn more about our pipeline

Innate Cell Engagers

AFM13

Disease Target CD30Immune Cell Target CD16A
Hodgkin lymphoma + PD-1
Phase 1
Hodgkin lymphoma
Phase 2
CD30+ lymphoma + adoptive NK cells
Pre-IND
CD30+ lymphoma
Phase 2

AFM24

Disease Target EGFRwtImmune Cell Target CD16A
Solid tumors
Pre-IND

AFM26

Disease Target BCMAImmune Cell Target CD16A
Multiple Myeloma
Pre-IND
Affimed programs
Partnered programs

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay